In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies

In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies

Background Colorectal cancer (CRC) is one of the most prevalent and deadly tumors worldwide. The majority of CRC is resistant to anti-programmed cell death-1 (PD-1)-based cancer immunotherapy, with approximately 15% with high-microsatellite instability, high tumor mutation burden, and intratumoral l...

Full description

Bibliographic Details
Main Authors: Nicola Normanno, Fabiana Tatangelo, Piera Maiolino, Stefania Scala, Caterina Ieranò, Dario Righelli, Crescenzo D'Alterio, Maria Napolitano, Luigi Portella, Giuseppina Rea, Federica Auletta, Sara Santagata, Anna Maria Trotta, Giuseppe Guardascione, Federica Liotti, Nella Prevete, Antonio Luciano, Antonio Barbieri, Annabella Di Mauro, Cristin Roma, Riziero Esposito Abate, Roberto Pacelli, Rosa Marina Melillo
Format: Article
Language:English
Published: BMJ Publishing Group 2022-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/3/e004032.full

Internet

https://jitc.bmj.com/content/10/3/e004032.full

Similar Items